Merus BV is a biotechnology company based in the Netherlands. It develops therapeutic monoclonal antibodies that address multiple targets in the treatment of cancer. The Company's technology base includes transgenic MeMo mouse, which produces therapeutic human antibodies. The technologies are used to create the Company’s products, notably Biclonics, antibodies used for the treatment of tumors. The Company’s antibody pipeline includes MCLA-12 used for the treatment of solid tumors, which is phase I/II development; MCLA-117, used for the treatment of acute myeloid leukemia, which is in the investigational new drug (IND) phase; MCLA-122, MCLA-134 and MCLA-145, used for the treatment of solid tumors, which is in the discovery phase; and MCLA-114, used for the treatment of multiple myeloma, which is in the discovery phase. Investors include Bay City Capital, Novartis, Pfizer, AGLAIA, Johnson & Johnson and Life Sciences Partners.